Live Breaking News & Updates on Andrew Nierenberg

Stay updated with breaking news from Andrew nierenberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NRX-101: First Antidepressant to Lower Suicidality in Bipolar Depression

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality. ....

United States , Miami Beach , New York , Andrew Nierenberg , Jonathan Javitt , Drug Administration , American Psychiatric Association , Dauten Family Center , Nrx Pharmaceuticals Nasdaq , Psychiatry At Harvard Medical School , American Society Of Clinical Psychopharmacology , Nrx Pharmaceuticals , Massachusetts General Hospital , American Society , Clinical Psychopharmacology , Chief Scientist , Bipolar Treatment Innovation , Harvard Medical School , Columbia Suicide Severity Rating Scale , Effect Size , Barnes Akathisia Rating , Psychiatric Association , Presents Landmark Trial , Clinical Psychopharmacology Annual Meeting , First Oral Antidepressant Demonstrated , Reduce Suicidality ,

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United States , North Carolina , France General , Jonathan Javitt , Dennis Mcbride , Richard Narido , Matthew Duffy , Michael Manyak , Fondation Fondamental , Dan Javitt , Andrew Nierenberg , Stephen Willard , Tim Moore , Nephron Pharmaceuticals , Head Of Bipolar Research At Harvard Mass , Office Of Undersecretary Defense , Defense Advanced Research Projects Agency , Department Of Defense , Us Navy , Harvard University , Nrx Pharmaceuticals , Lotus Pharmaceuticals , Nrx Pharmaceuticals Inc , Northwestern University , Head Of Urology At George Washington University , Columbia University ,

NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar. ....

United States , Jonathan Javitt , Matthew Duffy , Andrew Nierenberg , Jeremy Feffer , Exchange Commission , Lotus Pharmaceuticals Inc , Therapeutics Inc , Alvogen Inc , Nrx Pharmaceuticals , Us National Institutes Of Health , Nrx Pharmaceuticals Inc , Specialty Pharmaceutical Company , Securities Exchange , Treatment Resistant Bipolar Depression Study , Breakthrough Therapy Designation , Fast Track Designation , Biomarker Letter , Special Protocol Agreement , Suicidal Treatment Resistant Bipolar , Severe Bipolar Depression , Acute Suicidal Ideation , Special Protocol , New Drug , Chief Scientist , New Drug Application ,

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Jonathan Javitt , Andrew Nierenberg , Nrx Pharmaceuticals , Alvogen Inc , Nrx Pharmaceuticals Inc , Nrxp Nrx Pharmaceuticals , Lotus Pharmaceuticals Inc , Treatment Resistant Bipolar Depression Study , Lotus Pharmaceuticals , Breakthrough Therapy Designation , Fast Track Designation , Biomarker Letter , Special Protocol Agreement , Suicidal Treatment Resistant Bipolar , Severe Bipolar Depression , Acute Suicidal Ideation , Special Protocol , New Drug , Chief Scientist , New Drug Application , Principal Investigator , Harvard Massachusetts General , Montgomery Asberg Depression Rating Scale , Clinical Global Impression Suicidality Scale ,

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression -January 22, 2024 at 06:49 am EST

Exceeded originally target enrollment with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafterPositive. ....

United States , Andrew Nierenberg , Jonathan Javitt , Alvogen Pharmaceuticals , Prnewswire Nrx Pharmaceuticals Inc , Nrxp Nrx Pharmaceuticals , Us National Institutes Of Health , Nrx Pharmaceuticals Inc , Source Nrx Pharmaceuticals , Nrx Pharmaceuticals , Suicidal Treatment Resistant Bipolar , Breakthrough Therapy Designation , Chief Scientist , Principal Investigator , Harvard Massachusetts General , Clinical Global Impression Suicidality Scale , Breakthrough Therapy , New Drug Application , Fast Track Designation , Securities Litigation Reform Act ,